Item 1.01. Entry into a
Material Definitive Agreement.
On
February 2, 2021, Pluristem Therapeutics Inc., or the Company, entered into a securities purchase agreement, or the Securities
Purchase Agreement, with certain institutional investors, or the Investors, pursuant to which the Company agreed to issue and sell,
in a registered direct offering, or the Offering, by the Company directly to the Investors, 4,761,905 shares of common stock, or
the Shares, at a purchase price per Share of $6.30, for gross proceeds of approximately
$30 million before the deduction of fees and Offering expenses. The Securities Purchase Agreement contains customary representations,
warranties and agreements by the Company and customary conditions to closing. The closing of the Offering is expected to occur
on February 4, 2021, subject to customary closing conditions.
In
connection with the Offering, the Company entered into a placement agency agreement, or the Placement Agency Agreement, with A.G.P./Alliance
Global Partners, or the Placement Agent, pursuant to which the Company agreed to pay the Placement Agent a cash fee equal to 6%
of the aggregate gross proceeds raised from the sale of the securities sold in the Offering. The Placement Agency Agreement
contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification
obligations of the Company and the Placement Agents, including for liabilities under the Securities Act of 1933, as amended, other
obligations of the parties and termination provisions.
The
Company intends to use the net proceeds from the Offering for working capital. The Offering is being made pursuant to the Company’s
shelf registration statement on Form S-3 (Registration No. 333-239890), which was declared effective by the Securities and Exchange
Commission on July 23, 2020.
Under
the Securities Purchase Agreement and Placement Agency Agreement, the Company is prohibited, for a period of 45 days from the closing,
with respect to sales under its existing Open Market Sales AgreementSM, and 60 days after the closing, from issuing,
entering into any agreement to issue or announcing the issuance or proposed issuance of any shares of common stock or any other
securities that are at any time convertible into, or exercisable or exchangeable for, or otherwise entitle the holder thereof to
receive common stock, without the prior written consent of the placement agents or the investors participating in the Offering,
subject to specific exceptions.
The
Securities Purchase Agreement and Placement Agency Agreement are included as exhibits to this Current Report on Form 8-K to provide
investors and security holders with information regarding their terms. It is not intended to provide any other factual information
about the Company. The representations, warranties and covenants contained in the Securities Purchase Agreement and Placement Agency
Agreement, respectively, were made only for purposes of such agreements and as of specific dates, were solely for the benefit of
the parties to the Securities Purchase Agreement and Placement Agency Agreement, and may be subject to limitations agreed upon
by the parties. The foregoing description is qualified in its entirety by reference to the Securities Purchase Agreement and Placement
Agency Agreement, copies of which are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K and which
are hereby incorporated by reference into this Item 1.01.
A
copy of the legal opinion of Sullivan & Worcester LLP relating to the legality of the issuance and sale of the Shares is filed
as Exhibit 5.1 hereto.
This
Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any
sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or jurisdiction.